Viral load decrease in SARS‐CoV‐2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents

BACKGROUND: The efficacy on the Omicron variant of the approved early‐ coronavirus disease 2019 (COVID‐19) therapies, especially monoclonal antibodies, has been challenged by in vitro neutralization data, while data on in vivo antiviral activity are lacking. MATERIALS AND METHODS: We assessed potent...

Descripción completa

Detalles Bibliográficos
Autores principales: Valentina, Mazzotta, Alessandro, Cozzi Lepri, Francesca, Colavita, Silvia, Rosati, Eleonora, Lalle, Claudia, Cimaglia, Jessica, Paulicelli, Ilaria, Mastrorosa, Serena, Vita, Lavinia, Fabeni, Alessandra, Vergori, Gaetano, Maffongelli, Fabrizio, Carletti, Simone, Lanini, Emanuela, Caraffa, Eugenia, Milozzi, Raffaella, Libertone, Pierluca, Piselli, Enrico, Girardi, AnnaRosa, Garbuglia, Francesco, Vaia, Fabrizio, Maggi, Emanuele, Nicastri, Andrea, Antinori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539310/
https://www.ncbi.nlm.nih.gov/pubmed/36184918
http://dx.doi.org/10.1002/jmv.28186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539310/
https://www.ncbi.nlm.nih.gov/pubmed/36184918
http://dx.doi.org/10.1002/jmv.28186

Ejemplares similares